DK1404377T3 - Forbedrede chelatorkonjugater - Google Patents

Forbedrede chelatorkonjugater

Info

Publication number
DK1404377T3
DK1404377T3 DK02745600T DK02745600T DK1404377T3 DK 1404377 T3 DK1404377 T3 DK 1404377T3 DK 02745600 T DK02745600 T DK 02745600T DK 02745600 T DK02745600 T DK 02745600T DK 1404377 T3 DK1404377 T3 DK 1404377T3
Authority
DK
Denmark
Prior art keywords
chelator conjugates
improved
improved chelator
radiometal
conjugates
Prior art date
Application number
DK02745600T
Other languages
Danish (da)
English (en)
Inventor
Torgrim Engell
Colin Mill Archer
Harry John Wadsworth
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Application granted granted Critical
Publication of DK1404377T3 publication Critical patent/DK1404377T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/36—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicinal Preparation (AREA)
DK02745600T 2001-07-10 2002-07-10 Forbedrede chelatorkonjugater DK1404377T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0116815.2A GB0116815D0 (en) 2001-07-10 2001-07-10 Improved chelator conjugates

Publications (1)

Publication Number Publication Date
DK1404377T3 true DK1404377T3 (da) 2006-01-30

Family

ID=9918227

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02745600T DK1404377T3 (da) 2001-07-10 2002-07-10 Forbedrede chelatorkonjugater

Country Status (21)

Country Link
US (2) US7597875B2 (fr)
EP (1) EP1404377B1 (fr)
JP (1) JP5015409B2 (fr)
KR (1) KR100892009B1 (fr)
CN (4) CN101537190A (fr)
AT (1) ATE304866T1 (fr)
AU (1) AU2002317317B2 (fr)
BR (1) BR0210965A (fr)
CA (1) CA2450690C (fr)
DE (1) DE60206272T2 (fr)
DK (1) DK1404377T3 (fr)
ES (1) ES2250671T3 (fr)
GB (1) GB0116815D0 (fr)
HK (1) HK1064585A1 (fr)
HU (1) HU228850B1 (fr)
IL (1) IL159388A0 (fr)
MX (1) MXPA04000210A (fr)
NO (1) NO334093B1 (fr)
RU (1) RU2298012C2 (fr)
WO (1) WO2003006070A2 (fr)
ZA (1) ZA200400143B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2433657A1 (fr) 2001-01-05 2002-07-11 Duke University Agent ameliorateur de contraste en imagerie par resonance magnetique
HU230901B1 (hu) * 2001-07-10 2019-01-28 Ge Healthcare Limited Peptidalapú vegyületek és ezeket tartalmazó gyógyszerkészítmények
NO20030115D0 (no) * 2003-01-09 2003-01-09 Amersham Health As Kontrastmiddel
GB0416062D0 (en) 2004-07-19 2004-08-18 Amersham Plc Improved N4 chelator conjugates
US7785566B2 (en) 2003-11-06 2010-08-31 Ge Healthcare, Inc. Pharmaceutical compounds
US7431914B2 (en) 2003-11-24 2008-10-07 Ge Healthcare As Contrast agent
WO2005084715A2 (fr) * 2004-03-04 2005-09-15 Ge Healthcare As Composes pharmaceutiques
JP5116480B2 (ja) * 2004-11-22 2013-01-09 ジーイー・ヘルスケア・アクスイェ・セルスカプ 造影剤
EP1896380B1 (fr) * 2005-06-08 2012-02-29 GE Healthcare Limited Procédé d'utilisation de monoxyde de carbone [11c]dans le marquage de la synthèse d'esters marqués 11c-par carbonylation radicalaire sensibilisée photoinduite
GB0515974D0 (en) * 2005-08-03 2005-09-07 Ge Healthcare Ltd Compounds and imaging methods
US8124806B2 (en) 2006-02-15 2012-02-28 Ge Healthcare As Contrast agents
US7943117B2 (en) * 2006-06-08 2011-05-17 Atomic Energy Council—Institute of Nuclear Research Method for testing radiochemical purity of Tc-99m-TRODAT-1
RU2009119917A (ru) * 2006-12-11 2011-01-20 ДжиИ Хелткер АС (NO) Соединения на основе меченных радиоактивным изотопом пептидов и их применения
WO2010063069A1 (fr) 2008-12-02 2010-06-10 The University Of Melbourne Conjugués macrocycliques contenant de l'azote comme produits radiopharmaceutiques
GB0922014D0 (en) 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
WO2012013701A1 (fr) * 2010-07-27 2012-02-02 Ge Healthcare Limited Compositions radiopharmaceutiques
GB201103696D0 (en) * 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201110767D0 (en) 2011-06-24 2011-08-10 Ge Healthcare Ltd Infection imaging
US20130195756A1 (en) 2012-01-31 2013-08-01 General Electric Company 99mTc IMAGING AGENTS AND METHODS OF USE
CA2901231C (fr) * 2013-02-15 2020-06-23 Thomas Jefferson University Trousse comportant des compositions lyophilisees destinees a l'imagerie de tumeur
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
EP3131585B1 (fr) 2014-03-19 2020-07-15 Universität Zürich Agents de chélation bifonctionnels polydentés dans le diagnostic et la thérapie radionucléide
EP3790975A4 (fr) 2018-05-08 2022-10-26 University of Miami Matériaux et procédés pour l'administration d'acides nucléiques thérapeutiques à des tissus
EP3793619A4 (fr) 2018-05-16 2022-01-12 Emory University Dérivés de styrylbenzothiazole et leurs utilisations en imagerie
CN111548275A (zh) * 2020-05-27 2020-08-18 龙曦宁（上海）医药科技有限公司 一种2-（氨基甲基）-n1,n1-二甲基丙烷-1,3-二胺三盐酸盐的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1588978A (en) * 1977-07-19 1981-05-07 Ici Ltd Coating processes
DE3930674A1 (de) * 1989-09-11 1991-03-21 Diagnostikforschung Inst Bifunktionelle chelatbildner zur komplexierung von tc- und re-isotopen, verfahren zu ihrer herstellung und darstellung von konjugaten daraus sowie deren verwendung in diagnostik und therapie
US5808091A (en) * 1991-10-29 1998-09-15 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia localizing moiety
HUT73672A (en) * 1993-08-04 1996-09-30 Amersham Int Plc Radiometal complexes that localise in hypoxic tissue
ATE164833T1 (de) * 1994-01-12 1998-04-15 Bracco Int Bv Liganden und deren metallkomplexe
EP0738158B1 (fr) * 1994-01-12 2002-04-03 Amersham plc Agents biologiques de ciblage
BR9910468A (pt) 1998-05-15 2001-01-09 Nycomed Amersham Plc Composto, complexo radiometálico, preparação para administração em ser humano, kit, usos de um composto e de um complexo radiometálico do composto, e, fragmento de peptìdeo
US6783711B2 (en) * 2000-05-23 2004-08-31 Ge Osmonics, Inc. Process for preparing a sulfonamide polymer matrix
JP4009198B2 (ja) * 2001-03-08 2007-11-14 松下電器産業株式会社 インクジェット記録用インク、該インクの製造方法、並びに該インクを備えたインクカートリッジ及び記録装置

Also Published As

Publication number Publication date
RU2298012C2 (ru) 2007-04-27
KR100892009B1 (ko) 2009-04-07
NO334093B1 (no) 2013-12-09
US7597875B2 (en) 2009-10-06
DE60206272T2 (de) 2006-07-13
HUP0401265A3 (en) 2005-11-28
NO20035597L (no) 2004-03-03
US20040258619A1 (en) 2004-12-23
CA2450690A1 (fr) 2003-01-23
ZA200400143B (en) 2004-12-29
ES2250671T3 (es) 2006-04-16
MXPA04000210A (es) 2004-07-23
US20100040542A1 (en) 2010-02-18
KR20040017287A (ko) 2004-02-26
DE60206272D1 (de) 2005-10-27
GB0116815D0 (en) 2001-08-29
CN101607913B (zh) 2012-07-04
RU2003137592A (ru) 2005-05-20
CN1527727A (zh) 2004-09-08
WO2003006070A2 (fr) 2003-01-23
ATE304866T1 (de) 2005-10-15
CN101537190A (zh) 2009-09-23
CN100509061C (zh) 2009-07-08
BR0210965A (pt) 2004-06-08
CN101538313A (zh) 2009-09-23
EP1404377A2 (fr) 2004-04-07
US8852550B2 (en) 2014-10-07
AU2002317317B2 (en) 2005-11-17
IL159388A0 (en) 2004-06-01
JP2005500325A (ja) 2005-01-06
NO20035597D0 (no) 2003-12-16
CN101607913A (zh) 2009-12-23
WO2003006070A3 (fr) 2003-08-21
CA2450690C (fr) 2009-03-24
JP5015409B2 (ja) 2012-08-29
HK1064585A1 (en) 2005-02-04
EP1404377B1 (fr) 2005-09-21
HUP0401265A2 (hu) 2004-09-28
HU228850B1 (en) 2013-06-28

Similar Documents

Publication Publication Date Title
DK1404377T3 (da) Forbedrede chelatorkonjugater
DK1791571T3 (da) Radiofluorinerede peptider
DE60230890D1 (de) Indolizine als kinaseproteinhemmer
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
MXPA05009682A (es) Metodos de radiofluorinacion de vectores biologicamente activos.
BRPI0411897A (pt) pirroldihidroisoquinolinas como inibidores de pde10
ECSP034600A (es) Compuestos de lactama
CL2013002895A1 (es) Compuestos derivados de 7,8-dihidro-5h-pteridin-6-ona, utiles como intermediarios en la sintesis de compuestos derivados de pteridinona (divisional de la solicitud 3123-2005).
DE50202328D1 (de) Amidofunktionelle aminopolydiorganosiloxane
BRPI0307702B8 (pt) formulações de solução contendo anticorpo
MA30042B1 (fr) Composes calcilytiques
WO2003104425A3 (fr) Nouveaux anticorps anti-cd22 stables
DE60210598D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
DE60322562D1 (de) Konjugate von tc komplexen und zielgerichtete einheiten und ihre verwendung in nmr-diagnostik
TR199901017A2 (xx) B�cek ilac� terkibi.
DE60213084D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
RS20060195A (en) Imidazopyridine-derivatives as inducible no-synthase inhibitors
ID27733A (id) Metoksiminofenilasetamida
ITMI20030827A1 (it) Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
NO20021429D0 (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
EA200400764A1 (ru) 1,3-диарилпроп-2-ен-1-оны, композиция на их основе и применение
HN1999000157A (es) 1,2,3 tetrahidroquinolinas 2 - sustituidas 4 - amino sustituidas.
ITMI20030851A1 (it) Kit per impedire di russare, nonche' procedimento per la sua realizzazione.
UA115859C2 (uk) Розчинний поліпептид, який зв'язує активін а, та композиція, що його містить